Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 September;58(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 September;58(3):310-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 September;58(3):310-8

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT

Froeling V. 1, Röttgen R. 1, 2, Collettini F. 1, Rothe J. 2, Hamm B. 1, Brenner W. 2, Schreiter N. F. 2

1 Department of Radiology, Charité Medical University, Berlin, Germany; 2 Department of Nuclear Medicine, Charité Medical University, Berlin, Germany


PDF


AIM: Pancreatic neuroendocrine tumors (PNETs) pose a diagnostic challenge with respect to the physiologic somatostatin receptor expression in the uncinate process representing a potential pitfall for receptor imaging with PET/CT.
METHODS: We identified 49 PNETs from a total of 316 consecutive [68Ga]DOTATOC PET/CT examinations for whom the detections rates of PET and multiphase contrast enhanced (CE-) CT could be retrospectively compared and 38 PNETs for which SUVmax and SUVmax target-to-liver ratios could be calculated for the tumors and the uncinate process.
RESULTS: The detection rate of PET (83.7%) was higher than of the different CT phases (arterial: 59.2%, P=0.017; portal-venous: 38.8%, P<0.001; venous: 46.9%, P=0.001; multiphase: 71.4%, P=0.286). Compared to the other method PET revealed 28.6% additional lesions and multiphase CE-CT 16.3%. The portal-venous phase revealed only lesions that were also detected in the arterial or venous phase.
The detection rate for PNETs in the uncinate process (N.=9) was 66.7% for PET versus 55.6% for multiphase CE-CT. SUVmax and SUVmax target-to-liver ratios differed significantly (P<0.001) for PNETs (mean, range: SUVmax, 14.6, 1.4-69.3; SUVmax target-to-liver ratio, 3.2, 0.69-23.1) and uncinate process (4.32, 0.8-13.5; 0.94, 0.51-1.56), however with a wide overlap.
CONCLUSION: Patients with PNETs should undergo [68Ga]DOTATOC PET/CT with at least an arterial and venous phase CT scan. SUVmax and SUVmax target-to-liver ratios provide additional information but do no reliably separate PNETs from normal tracer uptake in the uncinate process.

inizio pagina